TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)
Luc M. Berclaz(Ludwig-Maximilians-Universität München), Thomas Knösel(LMU Klinikum)
Cited by 4
Related Papers
Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker Genes
|PLoS Computational Biology|2012|216
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia
|Endocrine Related Cancer|2019|83